|
|
|
|
|
|
|
|
|
|
|
By AR Welch, Editorial & Community Director, Advancing RNA
|
In my presentation, I argued that there are three lessons we can learn from Picasso that will also help our own industry mature. In the upcoming weeks, I plan to unpack these lessons, highlighting specific instances in which I see our industry taking these lessons to heart and making progress — starting here with lesson 1: Being Innovative Comes After We Master The Basics.
|
|
|
|
|
|
|
Panelists Tiffany Lucas and Ulrike Jägle address an audience question about when and how to approach the regulatory agencies for mRNA process development. In addition to listing the different FDA and EMA meeting opportunities available to sponsors, Jägle reminds us of one critical best practices sponsors shouldn’t forget when approaching the agencies.
|
|
|
|
|
|
By Life Science Connect Editorial Staff
|
Lipid nanoparticles (LNPs) face significant hurdles in clinical use due to challenges with their stability, manufacturing, and understanding how their complex characteristics impact therapeutic efficacy and safety.
|
|
|
|
|
|
|
|
|
|
|
|
5 Trends Impacting CMOs In 2025
|
|
Article | Jubilant HollisterStier
|
In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.
|
|
|
|
|
|
|
|
|
|
Improvement Of Self-Amplifying RNA With IVT Optimization
|
|
Poster | By J. Salnikov, R. Bushko, Y. Kong, J. Posy, Curia
|
This study on optimizing In-Vitro Transcription (IVT) conditions for self-amplifying RNAs to achieve high yields, low residual dsRNA, and improved potency, showcases how these advancements can enhance RNA-based therapies.
|
|
|
|
|
|
|
|
|
|
|
.png){kind=logo}
